Released Aug 5, 2020, after the close
10-Q filed Aug 5, 2020, 36 days after period end · 0001564590-20-036859
Q2 2020 · 10-Q
Revenue$39.38M$39.38M +1,178.4% vs Q2 2019+864.9% vs Q1 2020
Net Income$7.27M$7.27M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted$0.19$0.19 N/M vs Q2 2019N/M vs Q1 2020
Operating Income$6,579,000N/M
Operating Cash Flowderived-$23,116,000N/M
Free Cash Flowderived-$23,521,000N/M
Margins · derived
Operating margin16.7%+656.3 pt vs Q2 2019
Net margin18.5%+619.2 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $39.38M | $3.08M | $3.22M | $2.36M |
| Net Income | $7.27M | -$18.50M | -$26.81M | -$13.60M |
| EPS Diluted | $0.19 | -$0.72 | -$1.30 | -$780.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR